Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. AIDS 2011; 25: 73–79. 31  Puoti M, Cozzi-Lepri A, Arici C et al. Impact of lamivudine on the risk of liver related death in 2,041 HBsAg- and HIV-positive

individuals: results from an inter-cohort analysis. Antivir Ther 2006; 11: 567–574. 32  Marra F, Bruno R, Galastri S. gp120 induces directional migration of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis. Hepatology 2007; 46: Abstract A125. 33  Tuyama AC, Hong F, Saiman Y et al. Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus–induced liver fibrosis. Hepatology 2010; 52: PLX4032 nmr 612–622. 34  Marchetti G, Tincati C, Silvestri G. Microbial translocation in the pathogenesis

of HIV infection and AIDS. Clin Microbiol Rev 2013; 26: 2–18. 35  Aoyama T, Paik YH, Seki E. Toll-like receptor signaling and liver fibrosis. Gastroenterol Res Pract 2010; Article ID 192543, 8 pages. 36  Yuen MF, Yuan HJ, Wong D et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 2005; 54: 1610–1614. 37  Yuan HJ, Yuen MF, Wong D, Sablon E, Lai CL. The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese Progesterone selleck compound with chronic hepatitis B. J Viral Hepat 2005; 12: 373–379. 38  Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ for the Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678–686. 39  Gane EJ, Lim TH, Moyes C, Cunningham

C. 71 predictors of liver complications in childhood-acquired HBV infection in New Zealand Maori: results of 27 year longitudinal study. J Hepatol 2012; 56(Suppl 2): S31. 40  Liaw YF. Impact of therapy on the outcome of chronic hepatitis B. Liver Int 2013; 33(Suppl 1): 111–115. 41  Lacombe K, Rockstroh J. HIV and viral hepatitis coinfections: advances and challenges. Gut 2012; 61(Suppl 1): i47–i58. 42  Di Martino V, Thevenot T, Colin JF et al. Influence of HIV Infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 2002; 123: 1812–1822. 43  Johnson RM, Ristig MB, Overton ET, Lisker-Melman M, Cummings OW, Aberg JA. Safety and tolerability of sequential pegylated IFN-α2a and tenofovir for hepatitis B infection in HIV+ individuals. HIV Clin Trials 2007; 8: 173–181. 44  European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167–185. 45  Benhamou Y, Bochet M, Thibault V et al.